TGaS scooped up in private acquisition

KnowledgePoint360 has acquired TGaS Advisors, provider of data and advice to pharma sales and marketing organizations.

Terms were not disclosed. TGaS will become an operating division of the company.

“TGaS offers a unique model of developing data to assist pharmaceutical companies in benchmarking their activities against those of [competitors],” Jon Bigelow, president and CEO of KnowledgePoint360, told MM&M.

KnowledgePoint360—whose other divisions support publication plans, speakers bureau logistics, disease-state education and other medical-communications services—was created after the 2007 acquisition of Thomson Medical Education (TME) by KnowledgePoint360's majority owner, private-equity firm ABRY Partners.

Last year the firm shuttered Postgraduate Professional Services (PPS), its accredited medical education arm.
Bigelow said his firm is still looking to expand. “We moved out of the CME business last year, but [in] just about any other area of healthcare information, we are interested in being suppliers if we see we can provide value.”

Separately, TGaS was slated to field the Pharmaceutical Marketing Research Group's first State of the Industry Survey at the PMRG Institute meeting in late October, as well as online. PMRG will present results next March at its Annual National Conference.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.